| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10467
-Interferon (IFN
) potentiates the cytotoxicity of 5-fluorouracil (FUra) in vitro, and the combination has clinical efficacy in advanced colorectal cancer. We have reported previously an IFN
-mediated elevation in cellular FdUMP levels accompanied by the stimulation of thymidine phosphorylase (TP) activity in extracts from HT-29 human colon carcinoma cells treated with IFN
. We have now found that this effect of IFN
can be measured in vivo as an increase in thymine incorporation in intact cells. The increase was only 3-fold, however, compared to the 12-fold increase seen in TP activity in cell extracts. This suggested that the cosubstrate for TP, deoxyribose-1-phosphate, was rate limiting in the cells. Since the synthetic pathway of TP can also proceed via a transferase reaction, natural and modified deoxyribonucleosides were tested as deoxyribosyl donors. TP activity was measurable in cell extracts using deoxyinosine as cosubstrate with either thymine or FUra, although activity was only 10% of that measured with deoxyribose-1-phosphate. The pyrimidine analogue 5-propynyloxy-2'-deoxyuridine (PO-dUrd) had 15% of the maximal TP activity in cell extracts and also increased thymine incorporation in intact cells 10-fold. Both 2'-deoxyinosine and PO-dUrd potentiated the cytotoxicity of FUra by 811-fold. IFN
potentiated the cytotoxicity of FUra by 1.8-fold, and the combination of IFN
and PO-dUrd produced a 25-fold increase in the cytotoxicity of FUra. Neither the corresponding analogue riboside, 5-propynyloxyuridine, nor the analogue base, 5-propynyloxyuracil, had any effect on FUra cytotoxicity. There was a significant correlation between the ability of a nucleoside and/or IFN
combination to increase thymine incorporation and to reduce the 50% inhibitory concentration for FUra. IFN
and PO-dUrd also potentiated the inhibition by FUra of thymidylate synthase activity. These findings suggest that the use of a deoxyribonucleoside to provide the rate limiting cosubstrate would complement the stimulation of TP by IFN
, and together they should further enhance the antitumor activity of FUra.
1 Supported by NIH Grants CA54422 and CA36517, by Cancer Center Support Grant CA13330 from the National Cancer Institute, and by a grant from the Wendy Will Case Cancer Fund.
2 To whom requests for reprints should be sent, at Department of Oncology, Albert Einstein Cancer Center, 111 East 210th Street, Bronx, NY 10467.
Received 6/24/93. Accepted 1/17/94.
This article has been cited by other articles:
![]() |
J. Ciccolini, F. Fina, K. Bezulier, S. Giacometti, M. Roussel, A. Evrard, P. Cuq, S. Romain, P.-M. Martin, and C. Aubert Transmission of Apoptosis in Human Colorectal Tumor Cells Exposed to Capecitabine, Xeloda, Is Mediated via Fas Mol. Cancer Ther., September 1, 2002; 1(11): 923 - 927. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ciccolini, P. Cuq, A. Evrard, S. Giacometti, A. Pelegrin, C. Aubert, J.-P. Cano, and A. Iliadis Combination of Thymidine Phosphorylase Gene Transfer and Deoxyinosine Treatment Greatly Enhances 5-Fluorouracil Antitumor Activity in Vitro and in Vivo Mol. Cancer Ther., December 1, 2001; 1(2): 133 - 139. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ciccolini, L. Peillard, A. Evrard, P. Cuq, C. Aubert, A. Pelegrin, P. Formento, G. Milano, and J. Catalin Enhanced Antitumor Activity of 5-Fluorouracil in Combination with 2'-Deoxyinosine in Human Colorectal Cell Lines and Human Colon Tumor Xenografts Clin. Cancer Res., April 1, 2000; 6(4): 1529 - 1535. [Abstract] [Full Text] |
||||
![]() |
C. A. Presant, W. Wolf, V. Waluch, C. L. Wiseman, I. Weitz, and J. Shani Enhancement of Fluorouracil Uptake in Human Colorectal and Gastric Cancers by Interferon or by High-Dose Methotrexate: An In Vivo Human Study Using Noninvasive 19F-Magnetic Resonance Spectroscopy J. Clin. Oncol., January 14, 2000; 18(2): 255 - 255. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J.A. Harte, J. C. Matthews, S. M. O'Reilly, D.W. O. Tilsley, S. Osman, G. Brown, S. J. Luthra, F. Brady, T. Jones, and P. M. Price Tumor, Normal Tissue, and Plasma Pharmacokinetic Studies of Fluorouracil Biomodulation With N-Phosphonacetyl-L-aspartate, Folinic Acid, and Interferon Alfa J. Clin. Oncol., May 1, 1999; 17(5): 1580 - 1580. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-S.A. Ismail, C. J. Van Groeningen, A. Hardcastle, Q.-F. Ren, G. W. Aherne, F. Geoffroy, C. J. Allegra, and J. L. Grem. Modulation of Fluorouracil Cytotoxicity by Interferon-alpha and -gamma Mol. Pharmacol., February 1, 1998; 53(2): 252 - 261. [Abstract] [Full Text] |
||||
![]() |
L. Zhang, I. Z. MacKenzie, M. C. P. Rees, and R. Bicknell Regulation of the Expression of the Angiogenic Enzyme Platelet-Derived Endothelial Cell Growth Factor/ Thymidine Phosphorylase in Endometrial Isolates by Ovarian Steroids and Cytokines Endocrinology, November 1, 1997; 138(11): 4921 - 4930. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wadler and E. L. Schwartz New Advances in Interferon Therapy of Cancer Oncologist, August 1, 1997; 2(4): 254 - 267. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Schwartz, N. Baptiste, S. Wadler, and D. Makower Thymidine Phosphorylase Mediates the Sensitivity of Human Colon Carcinoma Cells to 5-Fluorouracil J. Biol. Chem., August 11, 1995; 270(32): 19073 - 19077. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |